Gara Jalqabaatti › Baayyee Ulfaataa › Mississippi
Qorannoo klinikaalii Baayyee Ulfaataa Mississippi keessatti
Qorannoo 11 Baayyee Ulfaataa f Mississippi keessatti hirmaatuu jiru.
Magaalota Mississippi keessatti
Takkalaa qorannoo (Ingiliffa)
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Prime Health and Wellness Sky Clinical Research Network Group, Fayette
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07684235Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Jackson Heart Clinic, Jackson
- Cardiology Associates of North Mississippi, Tupelo
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 45 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07037433A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dynamed Clinical Research, LP d/b/a DM Clinical Research, Gulfport
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06672549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fayette
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Gulfport
- AURORA-2 Clinical Site, Jackson
- AURORA-2 Clinical Site, Olive Branch
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Gulfport
- AURORA-1 Clinical Site, Jackson
- AURORA-1 Clinical Site, Olive Branch
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743463A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Olive Branch Family Medical Center, Olive Branch
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- DelRicht Research at Gulfport Memorial, Gulfport
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Gulfport
- ACCOMPLISH-2 Research Site, Ridgeland
Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07654374Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Sky Integrative Medical Center, Ridgeland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Gulfport
- ACCOMPLISH-1 Research Site, Ridgeland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT07654361Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.